Chris Shibutani, Goldman Sachs Senior Analyst, joins 'Closing Bell Overtime' to talk his top picks in the biotech sectors.

Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one...

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three...

High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth pro...

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.

After massive gains this year, Eli Lilly's stock has eclipsed many analysts' price targets. Still, the drugmaker has huge growth potential from its current product lineup.

Eli Lilly & Co. LLY, -3.42% and Boehringer Ingelheim said Friday that the U.S. Food and Drug Administration has approved their blockbuster drug Jardiance, already used for heart failure and diabete...

Eli Lilly & Co. LLY, -3.42% is best positioned to dominate the fast-growing U.S. market for obesity drugs into the 2030s, BMO Capital Markets analysts said in a report late Thursday. Although Novo ...

Eli Lilly & Co. (LLY) sued 10 medical spas, wellness centers, and compounding pharmacies across the U.S. for allegedly selling products that fraudulently claimed to be its popular diabetes drug, Mo...

Eli Lilly has taken legal action against spa owners, wellness centres and pharmacies for unauthorised versions of its best fat-busting drug Mounjaro. Four separate lawsuits have been filed against ...

The lawsuits come as Eli Lilly grapples with a shortage of Mounjaro in the U.S. due to skyrocketing demand.

Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the active ingredient in its diabetes ...

Pharmaceutical giant Eli Lilly & Co. NYSE: LLY stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly antici...

Eli Lilly's stock has performed well in the market, boosted by strong fundamental results and the success of Novo Nordisk's weight loss drug, Wegovy. Wegovy demonstrated a 20% reduction in the risk...